76 results on '"Kamina S"'
Search Results
2. Analogies in medicine: the rare paradigm of the Maltese (White) Cross
- Author
-
Batistatou, A., Kamina, S., and Charalabopoulos, K.
- Published
- 2006
3. Rectal metastases from lobular carcinoma of the breast: Report of a case and literature review
- Author
-
Bamias, A., Baltayiannis, G., Kamina, S., Fatouros, M., Lymperopoulos, E., Agnanti, N., Tsianos, E., and Pavlidis, N.
- Published
- 2001
4. Increased Expression of the bcl6 and CD10 Proteins Is Associated with Increased Apoptosis and Proliferation in Diffuse Large B-Cell Lymphomas
- Author
-
Bai, M, Agnantis, N J, Skyrlas, A, Tsanou, E, Kamina, S, Galani, V, and Kanavaros, P
- Published
- 2003
- Full Text
- View/download PDF
5. An unusual presentation of a patient with advanced prostate cancer, massive ascites and peritoneal metastasis: Case report and literature review
- Author
-
Petrakis, Dimitrios, Pentheroudakis, George, Kamina, S., Pappa, L., Papadiotis, E., Malamou-Mitsi, Vassiliki D., Pavlidis, Nicholas, Pavlidis, Nicholas [0000-0002-2195-9961], and Pentheroudakis, George [0000-0002-6632-2462]
- Subjects
Oncology ,Peritoneal metastasis ,medicine.medical_specialty ,Pathology ,lcsh:R5-920 ,Multidisciplinary ,Prostate cancer ,business.industry ,Ascites ,medicine.disease ,Peritoneal metastases ,Internal medicine ,Case report ,medicine ,Presentation (obstetrics) ,medicine.symptom ,business ,General ,lcsh:Medicine (General) ,lcsh:Science (General) ,lcsh:Q1-390 - Abstract
We describe the case of a patient with prostate cancer, ascites, omental and bone metastases, an extremely rare clinical variant that warrants further investigation, and review the relevant literature. © 2014. 6 3 517 521
- Published
- 2015
6. Solitary adrenal metastasis from early-stage dedifferentiated endometrial carcinoma: CT findings and review of the literature
- Author
-
Mouka, V., primary, Tsili, A. C., additional, Messinis, T., additional, Papoudou-Bai, Α., additional, Kamina, S., additional, and Argyropoulou, M. I., additional
- Published
- 2016
- Full Text
- View/download PDF
7. Docetaxel-induced enterocolitis: A serious and potentially fatal adverse event
- Author
-
Boussios, Stergios, Pentheroudakis, George, Kamina, S., Katsanos, K., Pavlidis, Nicholas, Pavlidis, Nicholas [0000-0002-2195-9961], Pentheroudakis, George [0000-0002-6632-2462], and Boussios, Stergios [0000-0002-2512-6131]
- Subjects
Adult ,Male ,Lung adenocarcinoma ,Letter ,Enterocolitis ,Febrile neutropenia ,Needle biopsy ,Docetaxel ,Colonoscopy ,Pemetrexed ,Carboplatin ,Multiple cycle treatment ,Lung neoplasms ,Antineoplastic agents ,Case report ,Drug dose reduction ,Humans ,Cancer patient ,Taxoids ,Drug fatality ,Middle aged ,Sigmoidoscopy ,Disease severity ,Cancer infiltration ,Human - Abstract
16 4 778 779
- Published
- 2011
8. Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: A translational Hellenic Cooperative Oncology Group (HeCOG) study
- Author
-
Pentheroudakis, G. Batistatou, A. Kalogeras, K.T. Kronenwett, R. Wirtz, R.M. Bournakis, E. Eleftheraki, A.G. Pectasides, D. Bobos, M. Papaspirou, I. Kamina, S. Gogas, H. Koutras, A.K. Pavlidis, N. Fountzilas, G.
- Subjects
skin and connective tissue diseases - Abstract
We evaluated the prognostic and predictive utility of β-tubulin isotype III (TUBB3) tumour gene transcription in early breast cancer patients enrolled in a randomised study. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was applied for assessment of TUBB3, ER, PgR, HER2 and MAPT messenger RNA and immunohistochemistry (IHC) for protein expression in 314 patients enrolled in trial HE10/97, evaluating epirubicin-alkylator adjuvant chemotherapy with or without paclitaxel. High TUBB3 mRNA status was associated with advanced T stage, high histological grade, low mRNA and protein levels of ER, PgR and MAPT, and high levels of HER2 (p < 0.001). At a median follow-up of 98 months, multivariate analysis showed high TUBB3 mRNA status to have prognostic significance for DFS (HR = 1.83, 95% CI 1.25-2.68, p = 0.002) and OS (HR = 1.71, 95% CI 1.03-2.83, p = 0.038), along with the number of involved axillary nodes, PgR mRNA status and tumour grade. TUBB3 mRNA levels did not predict benefit from inclusion of paclitaxel in adjuvant chemotherapy (test for interaction p = 0.96 for OS, p = 0.46 for DFS). Transcriptional activity of β-tubulin isotype III in early breast cancer is an adverse prognostic factor, though not a predictive one for taxane efficacy. © 2011 Springer Science+Business Media, LLC.
- Published
- 2011
9. Prognostic utility of beta-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study
- Author
-
Pentheroudakis, G., Batistatou, A., Kalogeras, K. T., Kronenwett, R., Wirtz, R. M., Bournakis, E., Eleftheraki, A. G., Pectasides, D., Bobos, M., Papaspirou, I., Kamina, S., Gogas, H., Koutras, A. K., Pavlidis, N., and Fountzilas, G.
- Subjects
Adult ,Tubulin/genetics/*metabolism ,Gene Expression Profiling ,Breast Neoplasms/*diagnosis/genetics/mortality/*pathology ,RNA, Messenger/metabolism ,Middle Aged ,Prognosis ,Survival Analysis ,Gene Expression Regulation, Neoplastic ,Young Adult ,Predictive Value of Tests ,Multivariate Analysis ,Humans ,Female ,Aged ,Neoplasm Staging ,Retrospective Studies - Abstract
We evaluated the prognostic and predictive utility of beta-tubulin isotype III (TUBB3) tumour gene transcription in early breast cancer patients enrolled in a randomised study. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was applied for assessment of TUBB3, ER, PgR, HER2 and MAPT messenger RNA and immunohistochemistry (IHC) for protein expression in 314 patients enrolled in trial HE10/97, evaluating epirubicin-alkylator adjuvant chemotherapy with or without paclitaxel. High TUBB3 mRNA status was associated with advanced T stage, high histological grade, low mRNA and protein levels of ER, PgR and MAPT, and high levels of HER2 (p < 0.001). At a median follow-up of 98 months, multivariate analysis showed high TUBB3 mRNA status to have prognostic significance for DFS (HR = 1.83, 95% CI 1.25-2.68, p = 0.002) and OS (HR = 1.71, 95% CI 1.03-2.83, p = 0.038), along with the number of involved axillary nodes, PgR mRNA status and tumour grade. TUBB3 mRNA levels did not predict benefit from inclusion of paclitaxel in adjuvant chemotherapy (test for interaction p = 0.96 for OS, p = 0.46 for DFS). Transcriptional activity of beta-tubulin isotype III in early breast cancer is an adverse prognostic factor, though not a predictive one for taxane efficacy. Breast Cancer Res Treat
- Published
- 2011
10. Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: A translational Hellenic Cooperative Oncology Group (HeCOG) study
- Author
-
Pentheroudakis, George, Batistatou, Anna, Kalogeras, K. T., Kronenwett, R., Wirtz, R. M., Bournakis, E., Eleftheraki, A. G., Pectasides, Dimitrios, Bobos, M., Papaspirou, I., Kamina, S., Gogas, H., Koutras, A. K., Pavlidis, Nicholas, Fountzilas, George, Pavlidis, Nicholas [0000-0002-2195-9961], Pentheroudakis, George [0000-0002-6632-2462], Department of Medical Oncology, Ioannina University Hospital, Department of Pathology, School of medicine [Thessaloniki], Aristotle University of Thessaloniki-Aristotle University of Thessaloniki, Translational Research Section, Hellenic Cooperative Oncology Group, Data Office, Siemens Healthcare Diagnostics, Sividon Diagnostics GmbH, Stratifyer Molecular Pathology GmbH, Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Section of Biostatistics, Section of Oncology, 2nd Department of Internal Medicine, Hippokration Hospital, University of Athens School of Medicine, Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Department of Histopathology, Alexandra Hospital, 1st Department of Medicine, Laiko General Hospital, University of Athens School of Medicine, Division of Oncology, Department of Medicine, and University Hospital, University of Patras Medical School
- Subjects
Oncology ,Β-tubulin isotype iii ,Messenger rna ,Progesterone receptor ,Multiple cycle treatment ,Breast cancer ,Medicine ,Protein analysis ,skin and connective tissue diseases ,Disease free survival ,β-tubulin isotype III ,Mastectomy ,Gene expression regulation ,Genetic transcription ,Prognosis ,Immunohistochemistry ,Gene expression profiling ,Gene Expression Regulation, Neoplastic ,Retrospective study ,Paclitaxel ,Granulocyte colony stimulating factor ,Reverse transcription polymerase chain reaction ,Beta tubulin ,Human ,medicine.medical_specialty ,Tumor gene ,Major clinical study ,Article ,Cancer grading ,Epidermal growth factor receptor 2 ,Prognostic/predictive factors ,Humans ,Predictive value of tests ,RNA, Messenger ,Cyclophosphamide ,Survival analysis ,Retrospective Studies ,Aged ,TUBB3 ,Follow up ,medicine.disease ,Survival Analysis ,Retrospective studies ,Tamoxifen ,Methotrexate ,chemistry ,Protein expression ,Gene expression ,Breast neoplasms ,Cancer Research ,Unclassified drug ,Messenger ,Partial mastectomy ,Beta tubulin iii ,Cancer staging ,chemistry.chemical_compound ,Tubulin ,Estrogen receptor ,Overall survival ,Middle aged ,Priority journal ,Middle Aged ,Excision repair cross complementing protein 1 ,Female ,Breast disease ,Fluorouracil ,Cancer tissue ,Adult ,Predictive value ,Histopathology ,Breast Neoplasms ,Young Adult ,Predictive Value of Tests ,Internal medicine ,Tau protein ,Early cancer ,Human tissue ,Neoplasm Staging ,Epirubicin ,Neoplastic ,Taxane ,Beta tubulin iii gene ,business.industry ,Gene Expression Profiling ,Cancer ,Translational research ,Genetic translation ,Adjuvant chemotherapy ,Drug efficacy ,Outcome assessment ,Young adult ,Multivariate analysis ,Multivariate Analysis ,Neoplasm staging ,Cancer patient ,Rna ,business ,Axillary lymph node ,Controlled study - Abstract
We evaluated the prognostic and predictive utility of β-tubulin isotype III (TUBB3) tumour gene transcription in early breast cancer patients enrolled in a randomised study. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was applied for assessment of TUBB3, ER, PgR, HER2 and MAPT messenger RNA and immunohistochemistry (IHC) for protein expression in 314 patients enrolled in trial HE10/97, evaluating epirubicin-alkylator adjuvant chemotherapy with or without paclitaxel. High TUBB3 mRNA status was associated with advanced T stage, high histological grade, low mRNA and protein levels of ER, PgR and MAPT, and high levels of HER2 (p < 0.001). At a median follow-up of 98 months, multivariate analysis showed high TUBB3 mRNA status to have prognostic significance for DFS (HR = 1.83, 95% CI 1.25-2.68, p = 0.002) and OS (HR = 1.71, 95% CI 1.03-2.83, p = 0.038), along with the number of involved axillary nodes, PgR mRNA status and tumour grade. TUBB3 mRNA levels did not predict benefit from inclusion of paclitaxel in adjuvant chemotherapy (test for interaction p = 0.96 for OS, p = 0.46 for DFS). Transcriptional activity of β-tubulin isotype III in early breast cancer is an adverse prognostic factor, though not a predictive one for taxane efficacy. © 2011 Springer Science+Business Media, LLC. 127 1 179 193
- Published
- 2011
11. Splenic marginal zone lymphoma in a patient with chronic hepatitis B
- Author
-
Christou, L., Kalambokis, G., Bai, M., Kamina, S., and Tsianos, E. V.
- Subjects
Adult ,Male ,Treatment Outcome ,Chemotherapy, Adjuvant ,Risk Factors ,Hepatitis B, Chronic/*complications/diagnosis ,Lymphoma, B-Cell, Marginal Zone/pathology/therapy/*virology ,Splenectomy ,Humans ,Bone Marrow Examination ,Antineoplastic Combined Chemotherapy Protocols/therapeutic use ,Splenic Neoplasms/pathology/therapy/*virology - Abstract
J Gastrointestin Liver Dis
- Published
- 2009
12. Microvessel density and immunohistochemical expression of angiogenic proteins VEGF, VEGFR1 and VEGFR2 in gastric adenocarcinoma
- Author
-
Lampri, E., Goussia, A., Sintou-Mantela, E., Balasi, E., Charchanti, A., Kamina, S., Capizzelo, A., Tsekeris, P., Briasoulis, E., Malamou-Mitsi, V., Agnantis, N. J., and Bai, M.
- Abstract
Virchows Archiv
- Published
- 2007
13. Incidence of apoptosis and cell proliferation in multiple myeloma: correlation with bcl-2 protein expression and serum levels of interleukin-6 (IL-6) and soluble IL-6 receptor
- Author
-
Chaidos, A. I., Bai, M. C., Kamina, S. A., Kanavaros, P. E., Agnantis, N. J., and Bourantas, K. L.
- Subjects
Aged, 80 and over ,Male ,Apoptosis ,Interleukin-6/*blood ,Humans ,Female ,Middle Aged ,Receptors, Interleukin-6/*blood ,Immunohistochemistry ,Multiple Myeloma/*metabolism/*pathology ,Cell Division ,Aged ,Proto-Oncogene Proteins c-bcl-2/*biosynthesis - Abstract
We evaluated the in vivo incidence of apoptosis and cell proliferation in multiple myeloma (MM) and investigated the correlation of both cellular events with histological tumour stage and grade, bcl-2 protein expression, serum IL-6 and sIL-6R. MATERIAL AND METHODS: The TUNEL method was used to assess apoptosis and immunohistochemistry to assess the expression of proliferating cell nuclear antigen (PCNA) and bcl-2 protein in 30 bone marrow biopsy specimens. The apoptotic index (AI) and proliferative index (PI) were defined as the percentage of TUNEL and PCNA positive plasma cells, respectively. RESULTS: The mean AI was 0.162% and the mean PI 27.44%. A positive correlation between AI and PI was found (r = 0.44, P = 0.017). PI was also correlated with tumour grade (P = 0.015). The mean bcl-2 protein expression was 70% and did not correlate with AI or PI, but was higher in specimens taken at first diagnosis than in specimens taken after response to treatment (P = 0.035). The mean serum IL-6 and sIL-6R values were 9.43 pg mL-1 and 47.27 ng mL-1, respectively. These parameters did not correlate with AI or PI. CONCLUSIONS: The results indicate that MM might be among the malignancies with very low incidence of apoptosis. Proliferative activity increased in parallel with tumour histological grade. A positive correlation between apoptosis and proliferation was observed, but the incidence of these two cellular events seems not to be related to the bcl-2 protein expression and the serum levels of IL-6 and sIL-6R. Eur J Haematol
- Published
- 2002
14. Near-absolute expression of the bcl-2 protein identifies a subgroup of stage II breast cancer patients with a most favorable outcome. Results of a clinicopathological study
- Author
-
Briasoulis, E., Agnantis, N. J., Zagorianakou, P., Kamina, S., Gorezi, M., Pavlidis, N., and Bai, M.
- Subjects
Adult ,Time Factors ,Breast Neoplasms/drug therapy/mortality/*pathology/surgery ,Middle Aged ,Prognosis ,Disease-Free Survival ,Proto-Oncogene Proteins c-bcl-2/*analysis ,Survival Rate ,Treatment Outcome ,Chemotherapy, Adjuvant ,Predictive Value of Tests ,Humans ,Female ,Aged ,Neoplasm Staging ,Retrospective Studies - Abstract
The clinical relevance of quantitative assessment of tumor-tissue expression of the bcl-2 protein in operated stage II breast cancer was investigated in this study. Thirty-five cases were studied by immunohistochemistry for the expression of bcl-2 protein and analyzed for disease outcome. One fourth (25%) of the cases were negative and 57% demonstrated near-absolute expression of the bcl-2 protein. No association was found between immunohistochemical detection of the protein with age, hormonal receptor status and tumor grading other than between bcl-2 and estrogen receptor expression (p=0.01). An impressively positive impact of near-absolute expression of bcl-2 on clinical outcome was identified. Our results provide evidence that quantitative assessment of bcl-2 expression constitutes a new approach in early breast cancer with potential clinical implications. We consider that molecular sub-staging of patients with stage II breast cancer by level of bcl-2 expression provides additional important prognostic information and prompts for investigation of its clinical significance on the issue of adjuvant systemic therapy. J Exp Clin Cancer Res
- Published
- 2001
15. Near-absolute expression of the bcl-2 protein identifies a subgroup of stage II breast cancer patients with a most favorable outcome. Results of a clinicopathological study
- Author
-
Briassoulis, E. Ch, Agnantis, Niki J., Zagorianakou, P., Kamina, S., Gorezi, M., Pavlidis, Nicholas, Bai, M. C., and Pavlidis, Nicholas [0000-0002-2195-9961]
- Subjects
Adult ,Survival rate ,Protein bcl 2 ,Disease-free survival ,Proto-oncogene proteins c-bcl-2 ,Cancer staging ,Article ,Quantitative assay ,Age ,Breast cancer ,Humans ,Chemotherapy ,Predictive value of tests ,Estrogen receptor ,Bcl-2 ,Treatment outcome ,Middle aged ,Adjuvant ,Breast-cancer ,Diagnostic value ,Aged ,Priority journal ,Time factors ,Prognosis ,Immunohistochemistry ,Retrospective studies ,Outcomes research ,Neoplasm staging ,Protein expression ,Female ,Breast neoplasms ,Human - Abstract
The clinical relevance of quantitative assessment of tumor-tissue expression of the bcl-2 protein in operated stage II breast cancer was investigated in this study. Thirty-five cases were studied by immunohistochemistry for the expression of bcl-2 protein and analyzed for disease outcome. One fourth (25%) of the cases were negative and 57% demonstrated near-absolute expression of the bcl-2 protein. No association was found between immunohistochemical detection of the protein with age, hormonal receptor status and tumor grading other than between bcl-2 and estrogen receptor expression (p=0.01). An impressively positive impact of near-absolute expression of bcl-2 on clinical outcome was identified. Our results provide evidence that quantitative assessment of bcl-2 expression constitutes a new approach in early breast cancer With potential clinical implications. We consider that molecular sub-staging of patients with stage II breast cancer by level of bcl-2 expression provides additional important prognostic information and prompts for investigation of its clinical significance on the issue of adjuvant systemic therapy. 20 3 341 344
- Published
- 2001
16. The clinical significance of bcl-2 overexpression in breast cancer patients - A retrospective study with long term follow up
- Author
-
Bai, M. C., Agnantis, Niki J., Zagorianakou, P., Kamina, S., Nonni, A. V., Pavlidis, Nicholas, Briassoulis, E. Ch, and Pavlidis, Nicholas [0000-0002-2195-9961]
- Subjects
Adult ,Conference paper ,Complete expression ,Protein bcl 2 ,Breast carcinoma ,Major clinical study ,Follow up ,Prognosis ,Cancer staging ,Immunohistochemistry ,Retrospective study ,Clinical feature ,Protein analysis ,Protein expression ,Female ,Bcl-2 ,Treatment outcome ,Disease course ,Controlled study ,Human ,Aged ,Priority journal - Abstract
We examined by immunohistochemistry the expression of the bcl-2 protein in sixty-eight cases of operated breast carcinoma patients (stage I, II and III) and correlated the findings with the prognosis. In 38.3% of the cases approximately all neoplastic cells were stained positive (complete expression). A strong impact of complete bcl-2 expression on the clinical outcome was identified (p=0.01). We consider this study as a new approach. There is evidence that the assessment of bcl-2 at the level of complete expression provides important prognostic information for breast carcinoma patients treated surgically. 7 1 94 98
- Published
- 2001
17. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices
- Author
-
Ioachim, E. E., Malamou-Mitsi, V., Kamina, S. A., Goussia, A. C., and Agnantis, N. J.
- Subjects
Receptor, erbB-2/analysis ,Neoplasm Proteins/*analysis ,Middle Aged ,Immunohistochemistry ,Proto-Oncogene Proteins c-bcl-2/*analysis ,Tumor Suppressor Protein p53/analysis ,Carcinoma, Lobular/chemistry ,Breast/chemistry ,Proliferating Cell Nuclear Antigen/analysis ,Proto-Oncogene Proteins/analysis ,Breast Neoplasms/*chemistry ,Humans ,Female ,Receptor, Epidermal Growth Factor/analysis ,Carcinoma, Ductal, Breast/chemistry ,Ki-67 Antigen/analysis ,Retinoblastoma Protein/analysis ,bcl-2-Associated X Protein - Abstract
Expression of bcl-2 protein was investigated and correlated with Bax, p53 and Rb proteins, c-erbB-2, EGFR and the proliferation indices PCNA, Ki-67 and MIB1 as well as with the conventional clinicopathological parameters in 95 cases for breast cancer tissue and 20 cases of benign hyperplastic lesions. Bcl-2 and Bax proteins immunoreactivity was detected in normal, hyperplastic and neoplastic breast epithelium. Expression of the bcl-2 protein was detected in 40% of carcinomas (> 10% positive neoplastic cells) and 85.2% of the benign hyperplastic lesions. Bax protein expression was detected in 8.1% of the carcinomas and 5.3% in the hyperplastic group. Rb and p53 proteins were detected in 75.5% and 45.5% of carcinomas. No relationship was observed between bcl-2 expression and patient's age, tumour size, tumour type and grade, lymph node status, Rb protein expression and proliferation indices. However, a strong positive relationship was detected between bcl-2 and Bax (p = 0.008), estrogen (ER) (p = 0.007) and progesterone receptors' (PgR) status (p = 0.0003). An inverse correlation with p53 protein (p = 0.004) was detected. Furthermore, a strong correlation was also observed between pRb and p53 (p = 0.001). The results indicate that in breast cancer bcl-2 protein expression may be under hormonal control. Since the expression is bcl-2 protein was inversely correlated with p53 protein expression, we suggest that bcl-2 may be related with favourable outcome in breast cancer. Anticancer Res
- Published
- 2000
18. p53 protein expression in human breast cancer: an immunohistochemical study including correlation with steroid receptor status, proliferation indices, collagen type IV, laminin, C-erbB-2 oncoprotein and Cathepsin D
- Author
-
Ioachim, E., primary, Skopelitou, A., additional, Kamina, S., additional, Nonni, A., additional, and Agnantis, N.J., additional
- Published
- 1998
- Full Text
- View/download PDF
19. p53 Expression in Hepatocellular Carcinoma in Greece
- Author
-
Skopelitou, A., primary, Hadjiyannakis, M., additional, Alexopoulou, V., additional, Kamina, S., additional, Krikoni, O., additional, and Agnantis, N.J., additional
- Published
- 1996
- Full Text
- View/download PDF
20. Cell cycle and apoptosis deregulation in classical Hodgkin lymphomas
- Author
-
Bai M, Alexandra Papoudou-Bai, Kitsoulis P, Horianopoulos N, Kamina S, Nj, Agnantis, and Kanavaros P
- Subjects
Apoptosis/*physiology ,Signal Transduction/physiology ,B-Lymphocytes/physiology ,Cell Cycle/*physiology ,Cell Differentiation/physiology ,Hodgkin Disease/*pathology/virology ,Humans ,Epstein-Barr Virus Infections/complications ,Reed-Sternberg Cells/physiology ,Herpesvirus 4, Human/physiology - Abstract
Classical Hodgkin lymphomas (cHL) have now been recognized as B-cell lymphomas with some exceptional cases of T-cell origin. In recent years, there has been accumulating evidence that Hodgkin and Reed-Sternberg (H/RS) cells, the presumed neoplastic-cell population in cHL, are characterized by a profound disturbance of the cell cycle and apoptosis regulation. The constitutive activation of the nuclear factor (NF)-kappaB pathway, which is considered to be involved in the proliferation and survival of H/RS cells. Moreover, substantial evidence that H/RS cells have defective cell cycle and apoptosis regulation has been provided by studies showing that these cells are characterized, in a large proportion of cases, by alterations of the p53, Rb and p27 tumor suppressor pathways, overexpression of cyclins involved in the G1/S and G2/M transition such as cyclins E, D2, D3, A and B1, overexpression of cyclin-dependent kinases such as CDK1, 2 and 6 and overexpression of anti-apoptotic proteins such as c-FLIP, bcl-xl, c-IAP2, X-linked I4P and survivin. Recent studies suggest that interleukin 13 (IL-13) is an important growth and survival factor in H/RS cells. Furthermore, the Epstein-Barr Virus (EBV), which is present in H/RS cells in about 30-50% of cHL, has been shown to affect the cell cycle and apoptosis regulation in cHL. The present review summarizes data with respect to the cell cycle and apoptosis deregulation in cHL. In Vivo
21. Cluster analysis of apoptosis-associated bcl2 family proteins in diffuse large B-cell lymphomas. Relations with the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes
- Author
-
Bai M, Skyrlas A, Nj, Agnantis, Kamina S, Kitsoulis P, and PANAGIOTIS KANAVAROS
- Subjects
Syndecans ,Neprilysin/biosynthesis ,Discriminant Analysis ,Apoptosis/physiology ,Lymphoma, B-Cell/*metabolism/pathology ,Immunohistochemistry ,Immunophenotyping ,Proto-Oncogene Proteins c-bcl-2/*biosynthesis ,Lymphoma, Large B-Cell, Diffuse/*metabolism/pathology ,Membrane Glycoproteins/biosynthesis ,Cluster Analysis ,Humans ,Proteoglycans/biosynthesis ,Syndecan-1 ,Cell Proliferation - Abstract
BACKGROUND: There is evidence that apoptotic mechanisms mediated by bcl2 family proteins are involved in the pathogenesis of diffuse large B-cell lymphomas (DLBCL). In order to gain further insight into the apoptosis profile of DLBCL, 79 cases were investigated to determine whether distinct clusters of the combined expression levels of bcl2 family proteins can be identified in these lymphomas. MATERIALS AND METHODS: The combined immunohistochemical expression levels of the proteins bax, bak, bad, bid, bcl2 and bcl-xl were evaluated by cluster and discriminant analysis. The produced clusters were analyzed in relation to the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes. RESULTS: Cluster analysis produced: a) a low expression (69/79 cases) and a high expression pro-apoptotic cluster (10/79 cases) for the combined expression levels of the pro-apoptotic proteins bax, bak, bad and bid and b) a low expression (37/76 cases) and a high expression antiapoptotic cluster (39/76 cases) for the combined expression levels of anti-apoptotic proteins bcl2 and bcl-xl. The decreasing order of discriminant power for the percentages of tumor cells expressing pro-apoptotic and anti-apoptotic proteins was % bax + cells> % bak+ cells> % bid+ cells> % bad+ cells and % bcl2+ cells> % bcl-xl+ cells, respectively. The high expression pro-apoptotic cluster was significantly associated with higher mean values of Ki67 (p=0.047) and cyclin A (p=0.033) expression. The high expression pro-apoptotic cluster was significantly associated with the germinal center B-cell bc16/CD10/MUM1/CD138 differentiation immunophenotype (p=0.043). CONCLUSION: This study identified distinct clusters of DLBCL with respect to the combined expression levels of the apoptosis-associated bcl2 family proteins. These findings, taken together with our previous observations that distinct clusters with respect to the apoptotic index and the proliferation profile are identified in DLBCL, indicate that subgroups with distinct cellular kinetic properties can be defined in these lymphomas. The cluster analysis approach might be useful for the identification of subgroups of DLBCL with different clinical behavior since increased proliferation and apoptosis were reported to be associated with aggressive tumor behavior in these lymphomas. Anticancer Res
22. B-cell differentiation, apoptosis and proliferation in diffuse large B-cell lymphomas
- Author
-
Bai M, Skyrlas A, Nj, Agnantis, Kamina S, Alexandra Papoudou-Bai, Kitsoulis P, and Kanavaros P
- Subjects
B-Lymphocytes/*pathology ,Lymphoma, Large B-Cell, Diffuse/*genetics/metabolism/*pathology ,Apoptosis/genetics ,Cell Differentiation/genetics ,Animals ,Humans ,Lymphoma, B-Cell/*genetics/metabolism/*pathology ,Oligonucleotide Array Sequence Analysis - Abstract
Diffuse large B-cell lymphomas (DLBCL) represent the most common type of adult non-Hodgkin's lymphomas in Western countries and are characterized by heterogeneous clinical, histological, immunophenotypic and genetic features. Recent investigations using cDNA and oligonucleotide microarrays have identified molecularly distinct groups of DLBCL with respect to the B-cell differentiation gene expression profile: the germinal center (GC) B-cell-like DLBCL, the activated B-cell-like DLBCL and the type 3 DLBCL. The GC B-cell-like DLBCL were characterized by the expression of genes of the normal GC B-cells, the activated B-cell-like DLBCL were characterized by the expression of genes that are normally induced luring in vitro activation of peripheral blood B-cells, while the type 3 DLBCL did not express either set of genes at a high level. Patients with GC B-cell-like DLBCL had more favorable clinical outcome than those with activated B-cell-like or type 3 DLBCL. Immunohistochemical studies have shown that the bc16/CD10/MUM1/CD138 B-cell differentiation immunophenotypes are prognostically relevant and may predict the cDNA classification in a sizable fraction of DLBCL. In the last few years, there has been accumulating molecular and immunohistochemical evidence indicating links between B-cell differentiation gene expression profiles and expression of apoptosis and cell cycle-associated genes in DLBCL. The present review summarizes data with respect to the relationships between B-cell differentiation, apoptosis and proliferation in DLBCL. Anticancer Res
23. Docetaxel-induced enterocolitis: A serious and potentially fatal adverse event
- Author
-
Stergios Boussios, Pentheroudakis, G., Kamina, S., Katsanos, K., and Pavlidis, N.
- Abstract
J BUON
24. Circulating Tumor DNA in the Management of Early-Stage Breast Cancer.
- Author
-
Vlataki K, Antonouli S, Kalyvioti C, Lampri E, Kamina S, Mauri D, Harissis HV, and Magklara A
- Subjects
- Humans, Female, Biomarkers, Tumor, Neoplasm Recurrence, Local, Liquid Biopsy methods, Breast Neoplasms diagnosis, Breast Neoplasms genetics, Breast Neoplasms pathology, Circulating Tumor DNA genetics
- Abstract
Liquid biopsies refer to the isolation and analysis of tumor-derived biological material from body fluids, most commonly blood, in order to provide clinically valuable information for the management of cancer patients. Their non-invasive nature allows to overcome the limitations of tissue biopsy and complement the latter in guiding therapeutic decision-making. In the past years, several studies have demonstrated that circulating tumor DNA (ctDNA) detection can be used in the clinical setting to improve patient prognosis and monitor therapy response, especially in metastatic cancers. With the advent of significant technological advances in assay development, ctDNA can now be accurately and reliably identified in early-stage cancers despite its low levels in the bloodstream. In this review, we discuss the most important studies that highlight the potential clinical utility of ctDNA in early-stage breast cancer focusing on early diagnosis, detection of minimal residual disease and prediction of metastatic relapse. We also offer a concise description of the most sensitive techniques that are deemed appropriate for ctDNA detection in early-stage cancer and we examine their advantages and disadvantages, as they have been employed in various studies. Finally, we discuss future perspectives on how ctDNA could be better integrated into the everyday oncology practice.
- Published
- 2023
- Full Text
- View/download PDF
25. Rapid Assessment of Resection Margins During Breast Conserving Surgery Using Intraoperative Flow Cytometry.
- Author
-
Vartholomatos G, Harissis H, Andreou M, Tatsi V, Pappa L, Kamina S, Batistatou A, Markopoulos GS, and Alexiou GA
- Subjects
- Breast Neoplasms pathology, Carcinoma, Ductal, Breast pathology, Female, Humans, Intraoperative Period, Neoplasm Grading, Reoperation, Breast Neoplasms diagnostic imaging, Breast Neoplasms surgery, Carcinoma, Ductal, Breast diagnostic imaging, Carcinoma, Ductal, Breast surgery, Flow Cytometry methods, Margins of Excision
- Abstract
Background: Positive margins are the most important factor for recurrence of the disease after breast-conserving surgery. Several methods have been developed throughout the years to evaluate the margin status during surgery in an attempt to assist the surgeon in excising the whole tumor at once, a goal that has not yet been accomplished., Patients and Methods: In our study, we compared intraoperative flow cytometry (iFC) with cytology and pathology in order to evaluate 606 samples of margins and tumors corresponding to 99 patients with invasive ductal carcinoma of no special type and invasive lobular carcinoma obtained from breast-conserving surgeries., Results: Using the pathology as the gold standard, flow cytometry had 93.3% sensitivity, 92.4% specificity, and 92.5% accuracy. Cytology had 82.3% sensitivity, 94.6% specificity, and 94.2% accuracy., Conclusions: Our data support the suggestion that iFC is a novel, reliable technique that allows rapid evaluation of the excision margins of lumpectomies, thus improving the precision of breast-conserving surgery. Among the advantages of iFC are that it does not rely on the expertise of a pathologist or cytologist, it is low cost, and it has no additional psychological effect on patients, because no re-operation is needed., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
26. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old.
- Author
-
Evangelou Z, Papoudou-Bai A, Karpathiou G, Kourea H, Kamina S, Goussia A, Harissis H, Peschos D, and Batistatou A
- Subjects
- Adult, Biomarkers, Tumor biosynthesis, Breast Neoplasms pathology, CD3 Complex biosynthesis, Female, Humans, Immunohistochemistry methods, Immunohistochemistry statistics & numerical data, Ki-67 Antigen biosynthesis, Prognosis, Receptors, Estrogen biosynthesis, Receptors, Progesterone biosynthesis, Retrospective Studies, B7-H1 Antigen biosynthesis, Breast Neoplasms metabolism, CD8-Positive T-Lymphocytes metabolism, Lymphocytes, Tumor-Infiltrating metabolism
- Abstract
Background/aim: To evaluate the association between programmed cell death ligand 1 (PD-L1) expression on both tumor cells (TC) and inflammatory cells (IC), tumor infiltrating lymphocytes (TILs), CD3
+ and CD8+ lymphocytes and other clinicopathological parameters in primary infiltrative breast cancer (IBC) of young women, a population shown to have a worse prognosis., Materials and Methods: A retrospective study was performed collecting data from patients younger than 40 years old. Forty-five young women with IBC were included. Whole tissue sections were used to evaluate all parameters., Results: Twenty percent (20%) of cases showed PD-L1 expression by tumor cells (PDL1TC) and 44.4% showed PD-L1 expression by immune cells (PDL1IC). Furthermore, 28.88% revealed high stromal TILs. PDL1TC and PDL1IC expression were significantly associated with tumor diameter and expression of estrogen (ER) and progesterone (PR) receptors and Ki67. PDL1TC expression was also associated with grade. High TILs were associated with tumor diameter, ER and Ki67 expression. PDL1TC, PDL1IC expression and TILs were associated with the density of CD3+ and CD8+ lymphocytes., Conclusion: Our results are similar to those of other age groups, as reported in the literature., (Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
27. Immunohistochemical expression of cell cycle proteins in multiple myeloma.
- Author
-
Pessach I, Papoudou-Bai A, Goussia A, Kamina S, Kyrtsonis MC, Bourantas KL, and Kanavaros P
- Subjects
- Biomarkers, Biopsy, Bone Marrow metabolism, Bone Marrow pathology, Cell Cycle Proteins genetics, Gene Expression, Humans, Immunohistochemistry, Multiple Myeloma diagnosis, Multiple Myeloma genetics, Cell Cycle Proteins metabolism, Multiple Myeloma metabolism
- Published
- 2015
- Full Text
- View/download PDF
28. Docetaxel-induced enterocolitis: a serious and potentially fatal adverse event.
- Author
-
Boussios S, Pentheroudakis G, Kamina S, Katsanos K, and Pavlidis N
- Subjects
- Antineoplastic Agents therapeutic use, Docetaxel, Humans, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Male, Middle Aged, Taxoids therapeutic use, Antineoplastic Agents adverse effects, Enterocolitis chemically induced, Taxoids adverse effects
- Published
- 2011
29. Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.
- Author
-
Pentheroudakis G, Batistatou A, Kalogeras KT, Kronenwett R, Wirtz RM, Bournakis E, Eleftheraki AG, Pectasides D, Bobos M, Papaspirou I, Kamina S, Gogas H, Koutras AK, Pavlidis N, and Fountzilas G
- Subjects
- Adult, Aged, Breast Neoplasms genetics, Breast Neoplasms mortality, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Middle Aged, Multivariate Analysis, Neoplasm Staging, Predictive Value of Tests, Prognosis, RNA, Messenger metabolism, Retrospective Studies, Survival Analysis, Tubulin genetics, Young Adult, Breast Neoplasms diagnosis, Breast Neoplasms pathology, Tubulin metabolism
- Abstract
We evaluated the prognostic and predictive utility of β-tubulin isotype III (TUBB3) tumour gene transcription in early breast cancer patients enrolled in a randomised study. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was applied for assessment of TUBB3, ER, PgR, HER2 and MAPT messenger RNA and immunohistochemistry (IHC) for protein expression in 314 patients enrolled in trial HE10/97, evaluating epirubicin-alkylator adjuvant chemotherapy with or without paclitaxel. High TUBB3 mRNA status was associated with advanced T stage, high histological grade, low mRNA and protein levels of ER, PgR and MAPT, and high levels of HER2 (p < 0.001). At a median follow-up of 98 months, multivariate analysis showed high TUBB3 mRNA status to have prognostic significance for DFS (HR = 1.83, 95% CI 1.25-2.68, p = 0.002) and OS (HR = 1.71, 95% CI 1.03-2.83, p = 0.038), along with the number of involved axillary nodes, PgR mRNA status and tumour grade. TUBB3 mRNA levels did not predict benefit from inclusion of paclitaxel in adjuvant chemotherapy (test for interaction p = 0.96 for OS, p = 0.46 for DFS). Transcriptional activity of β-tubulin isotype III in early breast cancer is an adverse prognostic factor, though not a predictive one for taxane efficacy.
- Published
- 2011
- Full Text
- View/download PDF
30. Pure small cell carcinoma of the prostate: a case report and literature review.
- Author
-
Capizzello A, Peponi E, Simou N, Ntaskagiannis D, Tasiou I, Kamina S, and Tsekeris P
- Abstract
Primary small cell carcinoma of the prostate (SCPCa) is a rare pathologic entity with unique clinical features and a poor prognosis. We present a case of a patient diagnosed with pure SCPCa treated with a combined chemo-radiotherapeutic approach. Pathological findings showed that the neoplastic cells exhibited positivity for pancytokeratin, synaptophysin, thyroid transcription factor-1 and CD56. Immunostaining for prostate-specific antigen was negative, while serum prostate-specific antigen was within normal limits. We review the available literature to gain additional information about diagnosis, treatment and prognosis of pure SCPCa.
- Published
- 2011
- Full Text
- View/download PDF
31. Diagnosis and endoscopic treatment of esophago-bronchial fistula due to gastric heterotopy.
- Author
-
Katsanos KH, Christodoulou DK, Kamina S, Maria K, Lambri E, Theodorou S, Tsampoulas K, Vasiliki M, and Tsianos EV
- Abstract
Heterotopic gastric mucosa patches are congenital gastrointestinal abnormalities and have been reported to occur anywhere along the gastrointestinal tract from mouth to anus. Complications of heterotopic gastric mucosa include dysphagia, upper gastrointestinal bleeding, upper esophageal ring stricture, adenocarcinoma and fistula formation. In this case report we describe the diagnosis and treatment of the first case of esophago-bronchial fistula due to heterotopic gastric mucosa in mid esophagus. A 40-year old former professional soccer player was referred to our department for treatment of an esophago-bronchial fistula. Microscopic examination of the biopsies taken from the esophageal fistula revealed the presence of gastric heterotopic mucosa. We decided to do a non-surgical therapeutic endoscopic procedure. A sclerotherapy catheter was inserted through which 1 mL of ready to use synthetic surgical glue was applied in the fistula and it closed the fistula opening with excellent results.
- Published
- 2010
- Full Text
- View/download PDF
32. Splenic marginal zone lymphoma in a patient with chronic hepatitis B.
- Author
-
Christou L, Kalambokis G, Bai M, Kamina S, and Tsianos EV
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Marrow Examination, Chemotherapy, Adjuvant, Hepatitis B, Chronic diagnosis, Humans, Lymphoma, B-Cell, Marginal Zone pathology, Lymphoma, B-Cell, Marginal Zone therapy, Male, Risk Factors, Splenectomy, Splenic Neoplasms pathology, Splenic Neoplasms therapy, Treatment Outcome, Hepatitis B, Chronic complications, Lymphoma, B-Cell, Marginal Zone virology, Splenic Neoplasms virology
- Published
- 2009
33. Sjogren's syndrome in a patient with ulcerative colitis and primary sclerosing cholangitis: Case report and review of the literature.
- Author
-
Katsanos KH, Saougos V, Kosmidou M, Doukas M, Kamina S, Asproudis I, and Tsianos EV
- Abstract
Inflammatory bowel disease has been reported to co-exist with other autoimmune diseases. Sjogren's syndrome is an autoimmune disorder characterized by xerostomy and/or xerophthalmy. Sjogren's syndrome occurring in IBD has been very rarely reported. A 45-year old woman diagnosed ten years ago with ulcerative pancolitis and primary sclerosing cholangitis was referred to our outpatient IBD clinic because of xerostomy but not for xerophthalmy for the previous three months. The patient had been under azathioprine maintenance treatment (2 mg/kg) and achieved long-term disease remission for the past 4 years. Patient clinical examination and laboratory tests were unremarkable. Salivary gland biopsy and complete ophthalmologic investigation were performed and the patient was diagnosed with Sjogren's syndrome. Understanding sicca manifestations in IBD is difficult since the pathogenesis of this intestinal disorder is not yet clear. Of these complex autoimmune phenomena which occur along with IBD it is quite difficult to categorize concomitant Sjogren's syndrome as primary or secondary and literature is conflicting. The possibility of Sjogren's syndrome should always be considered and properly investigated in patients diagnosed with inflammatory bowel disease who develop a constellation of constitutional sicca symptoms.
- Published
- 2009
- Full Text
- View/download PDF
34. Synchronous primary tumors of the kidney and the ovaries: Imaging findings.
- Author
-
Tsili AC, Charisiadi A, Koliopoulos G, Kamina S, Doukas M, Paraskevaidis E, and Tsampoulas K
- Abstract
The simultaneous presence of primary carcinomas in the same patient is uncommon and synchronous primary tumors involving the kidney and ovary are extremely rare. There are a few reports in the English literature of synchronous primary malignancies of the kidney and the ovaries, but no data regarding their imaging features. We present a case of an elderly woman, diagnosed with bilateral ovarian clear cell carcinomas and a simultaneous clear cell carcinoma of the right kidney, evaluated by multidetector CT and MR imaging.
- Published
- 2008
- Full Text
- View/download PDF
35. Early gastric carcinoma with oncocytic features and extensive metastases.
- Author
-
Batistatou A, Doukas M, Baltogiannis G, Panelos J, Kamina S, Charalabopoulos K, and Agnantis NJ
- Subjects
- Adenocarcinoma metabolism, Female, Humans, Liver Neoplasms secondary, Middle Aged, Neoplasm Staging, Stomach Neoplasms metabolism, Adenocarcinoma secondary, Stomach Neoplasms pathology
- Abstract
We present the case of a 63-year-old Caucasian woman with early gastric adenocarcinoma, suffering from extensive metastases at the time of initial presentation. Microscopic examination of the gastrectomy specimen revealed an invasive adenocarcinoma with oncocytic features. Interestingly, despite the fact that the carcinoma was pT1, it also was found to be N2, stage IV. The biologic behavior of oncocytic adenocarcinoma of the stomach is still unclear. We would like to present this case, so that its clinicopathological characteristics can be added to the few cases already published.
- Published
- 2007
- Full Text
- View/download PDF
36. Primary mantle cell lymphoma of the conjunctiva: a case report.
- Author
-
Aspiotis M, Gorezis S, Asproudis I, Tsanou E, Papadiotis E, Kamina S, Agnantis NJ, and Bai M
- Subjects
- Aged, Biomarkers, Tumor analysis, Biopsy, Conjunctiva chemistry, Conjunctival Neoplasms chemistry, Humans, Immunohistochemistry, Lymphoma, Mantle-Cell chemistry, Male, Conjunctiva pathology, Conjunctival Neoplasms pathology, Lymphoma, Mantle-Cell pathology
- Abstract
Primary non-Hodgkin's lymphomas of the conjunctiva are uncommon. They are almost exclusively extranodal marginal zone B-cell lymphomas/mucosa-associated lymphoid tissue lymphomas. In this study, we report an extremely rare case of conjunctival mantle cell lymphoma in a 78-year-old man, presenting as a unilateral epibulbar mass.
- Published
- 2006
- Full Text
- View/download PDF
37. Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case report and review of the literature.
- Author
-
Bai M, Katsanos KH, Economou M, Kamina S, Balli C, Briasoulis E, Kappas AM, Agnantis N, and Tsianos EV
- Subjects
- Adult, Humans, Immunosuppressive Agents, Male, Neoplasms, Second Primary diagnosis, Neoplasms, Second Primary virology, Crohn Disease complications, Herpesvirus 4, Human isolation & purification, Hodgkin Disease complications, Hodgkin Disease virology, Rectal Neoplasms virology
- Abstract
We present the case of a 35-year-old man with Crohn's disease diagnosed at the age of 27, several months after an operation for small-bowel adenocarcinoma. Seven years after the adenocarcinoma diagnosis, the patient presented with severe continuous anal pain and diarrhea. In parallel with antibiotic administration, the patient was given treatment with Infliximab, but without clinical symptom amelioration. Sigmoidoscopy and subsequent biopsies from an ulcerated rectal area supported the diagnosis of Epstein-Barr virus-positive (EBV+) primary Hodgkin's lymphoma. Infliximab administration was immediately discontinued and the patient underwent oncological follow-up and began a course of chemotherapy. Only a few cases with primary gastrointestinal Hodgkin's lymphoma in Crohn's disease patients have so far been reported, including a variety of scenarios on the causal relationship including disease duration, presence of EBV, long-term immunosuppressive treatment and, recently, anti-TNFalpha administration.
- Published
- 2006
- Full Text
- View/download PDF
38. Cell cycle and apoptosis deregulation in classical Hodgkin lymphomas.
- Author
-
Bai M, Papoudou-Bai A, Kitsoulis P, Horianopoulos N, Kamina S, Agnantis NJ, and Kanavaros P
- Subjects
- B-Lymphocytes physiology, Cell Differentiation physiology, Epstein-Barr Virus Infections complications, Herpesvirus 4, Human physiology, Hodgkin Disease virology, Humans, Reed-Sternberg Cells physiology, Signal Transduction physiology, Apoptosis physiology, Cell Cycle physiology, Hodgkin Disease pathology
- Abstract
Classical Hodgkin lymphomas (cHL) have now been recognized as B-cell lymphomas with some exceptional cases of T-cell origin. In recent years, there has been accumulating evidence that Hodgkin and Reed-Sternberg (H/RS) cells, the presumed neoplastic-cell population in cHL, are characterized by a profound disturbance of the cell cycle and apoptosis regulation. The constitutive activation of the nuclear factor (NF)-kappaB pathway, which is considered to be involved in the proliferation and survival of H/RS cells. Moreover, substantial evidence that H/RS cells have defective cell cycle and apoptosis regulation has been provided by studies showing that these cells are characterized, in a large proportion of cases, by alterations of the p53, Rb and p27 tumor suppressor pathways, overexpression of cyclins involved in the G1/S and G2/M transition such as cyclins E, D2, D3, A and B1, overexpression of cyclin-dependent kinases such as CDK1, 2 and 6 and overexpression of anti-apoptotic proteins such as c-FLIP, bcl-xl, c-IAP2, X-linked I4P and survivin. Recent studies suggest that interleukin 13 (IL-13) is an important growth and survival factor in H/RS cells. Furthermore, the Epstein-Barr Virus (EBV), which is present in H/RS cells in about 30-50% of cHL, has been shown to affect the cell cycle and apoptosis regulation in cHL. The present review summarizes data with respect to the cell cycle and apoptosis deregulation in cHL.
- Published
- 2005
39. B-cell differentiation, apoptosis and proliferation in diffuse large B-cell lymphomas.
- Author
-
Bai M, Skyrlas A, Agnantis NJ, Kamina S, Papoudou-Bai A, Kitsoulis P, and Kanavaros P
- Subjects
- Animals, Apoptosis genetics, Cell Differentiation genetics, Humans, Lymphoma, B-Cell metabolism, Lymphoma, Large B-Cell, Diffuse metabolism, Oligonucleotide Array Sequence Analysis, B-Lymphocytes pathology, Lymphoma, B-Cell genetics, Lymphoma, B-Cell pathology, Lymphoma, Large B-Cell, Diffuse genetics, Lymphoma, Large B-Cell, Diffuse pathology
- Abstract
Diffuse large B-cell lymphomas (DLBCL) represent the most common type of adult non-Hodgkin's lymphomas in Western countries and are characterized by heterogeneous clinical, histological, immunophenotypic and genetic features. Recent investigations using cDNA and oligonucleotide microarrays have identified molecularly distinct groups of DLBCL with respect to the B-cell differentiation gene expression profile: the germinal center (GC) B-cell-like DLBCL, the activated B-cell-like DLBCL and the type 3 DLBCL. The GC B-cell-like DLBCL were characterized by the expression of genes of the normal GC B-cells, the activated B-cell-like DLBCL were characterized by the expression of genes that are normally induced luring in vitro activation of peripheral blood B-cells, while the type 3 DLBCL did not express either set of genes at a high level. Patients with GC B-cell-like DLBCL had more favorable clinical outcome than those with activated B-cell-like or type 3 DLBCL. Immunohistochemical studies have shown that the bc16/CD10/MUM1/CD138 B-cell differentiation immunophenotypes are prognostically relevant and may predict the cDNA classification in a sizable fraction of DLBCL. In the last few years, there has been accumulating molecular and immunohistochemical evidence indicating links between B-cell differentiation gene expression profiles and expression of apoptosis and cell cycle-associated genes in DLBCL. The present review summarizes data with respect to the relationships between B-cell differentiation, apoptosis and proliferation in DLBCL.
- Published
- 2005
40. Proliferation profile of classical Hodgkin's lymphomas. Increased expression of the protein cyclin D2 in Hodgkin's and Reed-Sternberg cells.
- Author
-
Bai M, Tsanou E, Agnantis NJ, Kamina S, Grepi C, Stefanaki K, Rontogianni D, Galani V, and Kanavaros P
- Subjects
- Cell Cycle physiology, Cyclin A biosynthesis, Cyclin B biosynthesis, Cyclin B1, Cyclin D2, Hodgkin Disease pathology, Humans, Immunohistochemistry, Proliferating Cell Nuclear Antigen biosynthesis, Reed-Sternberg Cells pathology, Tumor Suppressor Protein p53 biosynthesis, Up-Regulation, Cell Proliferation, Cyclins biosynthesis, Hodgkin Disease metabolism, Reed-Sternberg Cells metabolism
- Abstract
There is accumulating evidence that Hodgkin's and Reed-Sternberg cells of classical Hodgkin's lymphomas (cHL) display multiple and concurrent alterations in different pathways and checkpoints of the cell cycle. However, the expression of cyclin D2 and its relation to other major cell cycle proteins has not been analyzed in cHL. The aim of the present study was to assess expression of cyclin D2, Ki67, cyclin A, cyclin B1, cyclin D1, cyclin D3, cyclin E, p53, Rb, p16 and p27 proteins in order to gain further insight into the proliferation profile of cHL. Overexpression of cyclin D2 in Hodgkin's and Reed-Sternberg cells was detected in 64/89 (72%) cases of cHL. This finding, in view of recent in vitro data showing that constitutive activation of nuclear factor (NF)-kB could upregulate cyclin D2 expression in part via signal transducer and activator of transcription (STAT)-5a, suggests that induction of cyclin D2 expression may support the proliferation of Hodgkin's and Reed-Sternberg cells. In addition, the present study showed that (1) increased p27 expression status was significantly correlated with higher levels of cyclin A expression (P=0.048) and (2) increased p53 expression status was significantly correlated with higher levels of cyclin A (P<0.001) and cyclin B1 (P=0.040) expression. The association between increased p27 and p53 expression status and higher expression levels of G2/M cyclins suggests that the impairment of the growth inhibitory activity of the p27 and p53 tumor suppressor pathways may promote the proliferation of Hodgkin's and Reed-Sternberg cells.
- Published
- 2004
- Full Text
- View/download PDF
41. Cluster analysis of apoptosis-associated bcl2 family proteins in diffuse large B-cell lymphomas. Relations with the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes.
- Author
-
Bai M, Skyrlas A, Agnantis NJ, Kamina S, Kitsoulis P, and Kanavaros P
- Subjects
- Apoptosis physiology, Cell Proliferation, Cluster Analysis, Discriminant Analysis, Humans, Immunohistochemistry, Immunophenotyping, Lymphoma, B-Cell pathology, Lymphoma, Large B-Cell, Diffuse pathology, Membrane Glycoproteins biosynthesis, Neprilysin biosynthesis, Proteoglycans biosynthesis, Syndecan-1, Syndecans, Lymphoma, B-Cell metabolism, Lymphoma, Large B-Cell, Diffuse metabolism, Proto-Oncogene Proteins c-bcl-2 biosynthesis
- Abstract
Background: There is evidence that apoptotic mechanisms mediated by bcl2 family proteins are involved in the pathogenesis of diffuse large B-cell lymphomas (DLBCL). In order to gain further insight into the apoptosis profile of DLBCL, 79 cases were investigated to determine whether distinct clusters of the combined expression levels of bcl2 family proteins can be identified in these lymphomas., Materials and Methods: The combined immunohistochemical expression levels of the proteins bax, bak, bad, bid, bcl2 and bcl-xl were evaluated by cluster and discriminant analysis. The produced clusters were analyzed in relation to the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes., Results: Cluster analysis produced: a) a low expression (69/79 cases) and a high expression pro-apoptotic cluster (10/79 cases) for the combined expression levels of the pro-apoptotic proteins bax, bak, bad and bid and b) a low expression (37/76 cases) and a high expression antiapoptotic cluster (39/76 cases) for the combined expression levels of anti-apoptotic proteins bcl2 and bcl-xl. The decreasing order of discriminant power for the percentages of tumor cells expressing pro-apoptotic and anti-apoptotic proteins was % bax + cells> % bak+ cells> % bid+ cells> % bad+ cells and % bcl2+ cells> % bcl-xl+ cells, respectively. The high expression pro-apoptotic cluster was significantly associated with higher mean values of Ki67 (p=0.047) and cyclin A (p=0.033) expression. The high expression pro-apoptotic cluster was significantly associated with the germinal center B-cell bc16/CD10/MUM1/CD138 differentiation immunophenotype (p=0.043)., Conclusion: This study identified distinct clusters of DLBCL with respect to the combined expression levels of the apoptosis-associated bcl2 family proteins. These findings, taken together with our previous observations that distinct clusters with respect to the apoptotic index and the proliferation profile are identified in DLBCL, indicate that subgroups with distinct cellular kinetic properties can be defined in these lymphomas. The cluster analysis approach might be useful for the identification of subgroups of DLBCL with different clinical behavior since increased proliferation and apoptosis were reported to be associated with aggressive tumor behavior in these lymphomas.
- Published
- 2004
42. Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl.
- Author
-
Bai M, Skyrlas A, Agnantis NJ, Kamina S, Tsanou E, Grepi C, Galani V, and Kanavaros P
- Subjects
- B-Lymphocytes chemistry, B-Lymphocytes immunology, B-Lymphocytes pathology, BH3 Interacting Domain Death Agonist Protein, Carrier Proteins analysis, Cell Cycle Proteins analysis, Cell Differentiation, Cell Division, Chi-Square Distribution, DNA-Binding Proteins analysis, Germinal Center chemistry, Germinal Center immunology, Humans, Immunohistochemistry, Immunophenotyping, Interferon Regulatory Factors, Lymphoma, B-Cell immunology, Lymphoma, B-Cell metabolism, Lymphoma, Large B-Cell, Diffuse immunology, Lymphoma, Large B-Cell, Diffuse metabolism, Membrane Proteins analysis, Neprilysin analysis, Proto-Oncogene Proteins analysis, Proto-Oncogene Proteins c-bcl-2 analysis, Transcription Factors analysis, bcl-2 Homologous Antagonist-Killer Protein, bcl-2-Associated X Protein, bcl-X Protein, Apoptosis, Germinal Center pathology, Lymphoma, B-Cell pathology, Lymphoma, Large B-Cell, Diffuse pathology, Proto-Oncogene Proteins biosynthesis
- Abstract
The aim of this study was to analyze the relations between differentiation immunophenotypes and the status of apoptosis and proliferation in diffuse large B-cell lymphomas. Therefore, the bcl6/CD10/MUM1/CD138 differentiation immunophenotypic profiles were studied in relation to (a) the apoptotic index, (b) the apoptosis-associated bcl2 family proteins bcl2, bcl-xl, bax, bak, bad and bid, (c) the proliferation index (Ki67) and (d) the cell cycle proteins cyclin A, cyclin B1, cyclin D3, cyclin E, p53, Rb, p16 and p27 in 79 cases of diffuse large B-cell lymphomas. Two major differentiation immunophenotypic profiles were distinguished: the germinal center B-cell-like profile; 31 cases (bcl6+/CD10+/-/MUM1-/CD138-: 29 cases and bcl6-/CD10+/MUM1-/CD138-: two cases) and the nongerminal center B-cell-like profile (bcl6+/-/CD10-/MUM1+/CD138-); 48 cases. The expression of bax, bak and bid and the apoptotic index were significantly higher in the germinal center B-cell-like profile than in the nongerminal center B-cell-like profile (P=0.045, 0.018, 0.003 and 0.034, respectively). In contrast, the expression of bcl-xl was significantly lower in the germinal center B-cell-like profile than in the nongerminal center B-cell-like profile (P=0.026). The expression of bcl6 and CD10 showed significant positive correlation with the expression of bax (r=0.659, P<0.001 and r=0.240, P=0.033, respectively), bak (r=0.391, P<0.001 and r=0.233, P=0.039, respectively) and bid (r=0.652, P<0.001 and r=0.238, P=0.035, respectively) and significant negative correlation with the expression of bcl-xl (r=-0.536, P<0.001 and r=-0.250, P=0.029, respectively). The expression of MUM1 showed significant negative correlation with the expression of bax (r=-0.276, P=0.014) and bid (r=-0.266, P=0.018) and significant positive correlation with the expression of bcl-xl (r=0.238, P=0.037). The above findings indicate that diffuse large B-cell lymphomas with germinal center B-cell-like immunophenotypic profile are associated with increased apoptosis status, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl., (Copyright 2004 USCAP, Inc.)
- Published
- 2004
- Full Text
- View/download PDF
43. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer.
- Author
-
Stefanou D, Batistatou A, Kamina S, Arkoumani E, Papachristou DJ, and Agnantis NJ
- Subjects
- Adenocarcinoma blood supply, Adenocarcinoma pathology, Aged, Antigens, CD34 metabolism, Humans, Immunoenzyme Techniques, Male, Microcirculation metabolism, Middle Aged, Neovascularization, Pathologic, Platelet Endothelial Cell Adhesion Molecule-1 metabolism, Prostatic Hyperplasia pathology, Prostatic Neoplasms blood supply, Prostatic Neoplasms pathology, Adenocarcinoma metabolism, Microcirculation pathology, Prostatic Hyperplasia metabolism, Prostatic Neoplasms metabolism, Vascular Endothelial Growth Factor A metabolism
- Abstract
Background: Tumor angiogenesis is an absolute requirement for tumor growth and a prognostic factor for various malignant neoplasms. Recent reports in the literature have addressed the importance of the VEGF system in benign prostatic hyperplasia (BPH) and adenocarcinoma, however the results are controversial. The aim of the present study was to determine and compare the levels of VEGF expression and vascularity in BPH and prostate carcinoma., Materials and Methods: We examined 60 prostate adenocarcinomas and 64 benign prostatic hyperplasias. Angiogenesis was estimated by determining microvessel counts (MVC), with the use of anti-CD31 and anti-CD34 antibodies. Expression of VEGF was also evaluated immunohistochemically., Results and Conclusion: Our data showed that angiogenesis was more prominent in carcinomas than in BPH. Furthermore, increased MVC was significantly associated with high-grade carcinomas. Angiogenesis was correlated with VEGF expression and it was, at least in part, mediated by the latter. Thus, prostate adenocarcinoma may represent a suitable neoplasm for antiangiogenic treatment in combination with conventional therapies.
- Published
- 2004
44. Intramural pregnancy with negative maternal serum b-HCG.
- Author
-
Dousias V, Stefos T, Chouliara S, Stefanou D, Kamina S, and Lolis D
- Subjects
- Chorionic Villi pathology, Female, Humans, Myometrium diagnostic imaging, Obstetric Surgical Procedures methods, Pregnancy, Pregnancy, Ectopic pathology, Ultrasonography methods, Chorionic Gonadotropin, beta Subunit, Human blood, Myometrium surgery, Pregnancy, Ectopic diagnosis, Pregnancy, Ectopic surgery
- Abstract
We report an extremely rare case of intramural pregnancy with negative maternal b-HCG value. The patient underwent a "myomectomy" but the pathology examination revealed chorionic villi consistent with ectopic pregnancy. Diagnosis is very difficult in cases with menorrhagia and especially when pregnancy is not suspected.
- Published
- 2003
- Full Text
- View/download PDF
45. Near-absolute expression of the bcl-2 protein identifies a subgroup of stage II breast cancer patients with a most favorable outcome. Results of a clinicopathological study.
- Author
-
Briasoulis E, Agnantis NJ, Zagorianakou P, Kamina S, Gorezi M, Pavlidis N, and Bai M
- Subjects
- Adult, Aged, Breast Neoplasms drug therapy, Breast Neoplasms mortality, Breast Neoplasms surgery, Chemotherapy, Adjuvant, Disease-Free Survival, Female, Humans, Middle Aged, Neoplasm Staging, Predictive Value of Tests, Prognosis, Retrospective Studies, Survival Rate, Time Factors, Treatment Outcome, Breast Neoplasms pathology, Proto-Oncogene Proteins c-bcl-2 analysis
- Abstract
The clinical relevance of quantitative assessment of tumor-tissue expression of the bcl-2 protein in operated stage II breast cancer was investigated in this study. Thirty-five cases were studied by immunohistochemistry for the expression of bcl-2 protein and analyzed for disease outcome. One fourth (25%) of the cases were negative and 57% demonstrated near-absolute expression of the bcl-2 protein. No association was found between immunohistochemical detection of the protein with age, hormonal receptor status and tumor grading other than between bcl-2 and estrogen receptor expression (p=0.01). An impressively positive impact of near-absolute expression of bcl-2 on clinical outcome was identified. Our results provide evidence that quantitative assessment of bcl-2 expression constitutes a new approach in early breast cancer with potential clinical implications. We consider that molecular sub-staging of patients with stage II breast cancer by level of bcl-2 expression provides additional important prognostic information and prompts for investigation of its clinical significance on the issue of adjuvant systemic therapy.
- Published
- 2001
46. In vivo cell kinetics in breast carcinogenesis.
- Author
-
Bai M, Agnantis NJ, Kamina S, Demou A, Zagorianakou P, Katsaraki A, and Kanavaros P
- Subjects
- Adult, Aged, Female, Fibrocystic Breast Disease pathology, Humans, Hyperplasia, Middle Aged, Neoplasm Invasiveness, Precancerous Conditions pathology, Apoptosis, Breast Neoplasms physiopathology, Carcinoma, Intraductal, Noninfiltrating physiopathology, Cell Division, Cell Transformation, Neoplastic pathology
- Abstract
Background: Disruption of the balance between apoptosis and proliferation is considered to be an important factor in the development and progression of tumours. In the present study we determined the in vivo cell kinetics along the spectrum of apparently normal epithelium, hyperplasia, preinvasive lesions and invasive carcinoma, in breast tissues affected by fibrocystic changes in which preinvasive and/or invasive lesions developed, as a model of breast carcinogenesis., Materials and Methods: A total of 32 areas of apparently normal epithelium and 135 ductal proliferative and neoplastic lesions were studied. More than one epithelial lesion per case were analyzed. The apoptotic index (AI) and the proliferative index (PI) were expressed as the percentage of TdT-mediated dUTP-nick end-labelling (TUNEL) and Ki-67-positive cells, respectively. The PI/AI (P/A index) was calculated for each case., Results: The AIs and PIs were significantly higher in hyperplasia than in apparently normal epithelium (P = 0.04 and P = 0.0005, respectively), in atypical hyperplasia than in hyperplasia (P = 0.01 and P = 0.04, respectively) and in invasive carcinoma than in in situ carcinoma (P < 0.001 and P < 0.001, respectively). The two indices were similar in atypical hyperplasia and in in situ carcinoma. The P/A index increased significantly from normal epithelium to hyperplasia (P = 0.01) and from preinvasive lesions to invasive carcinoma (P = 0.04) whereas it was decreased (non-significantly) from hyperplasia to preinvasive lesions. A strong positive correlation between the AIs and the PIs was found (r = 0.83, P < 0.001)., Conclusion: These findings suggest accelerating cell turnover along the continuum of breast carcinogenesis. Atypical hyperplasias and in situ carcinomas might be kinetically similar lesions. In the transition from normal epithelium to hyperplasia and from preinvasive lesions to invasive carcinoma the net growth of epithelial cells results from a growth imbalance in favour of proliferation. In the transition from hyperplasia to preinvasive lesions there is an imbalance in favour of apoptosis.
- Published
- 2001
47. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
- Author
-
Ioachim EE, Malamou-Mitsi V, Kamina SA, Goussia AC, and Agnantis NJ
- Subjects
- Breast chemistry, Carcinoma, Ductal, Breast chemistry, Carcinoma, Lobular chemistry, ErbB Receptors analysis, Female, Humans, Immunohistochemistry, Ki-67 Antigen analysis, Middle Aged, Proliferating Cell Nuclear Antigen analysis, Proto-Oncogene Proteins analysis, Receptor, ErbB-2 analysis, Retinoblastoma Protein analysis, Tumor Suppressor Protein p53 analysis, bcl-2-Associated X Protein, Breast Neoplasms chemistry, Neoplasm Proteins analysis, Proto-Oncogene Proteins c-bcl-2 analysis
- Abstract
Expression of bcl-2 protein was investigated and correlated with Bax, p53 and Rb proteins, c-erbB-2, EGFR and the proliferation indices PCNA, Ki-67 and MIB1 as well as with the conventional clinicopathological parameters in 95 cases for breast cancer tissue and 20 cases of benign hyperplastic lesions. Bcl-2 and Bax proteins immunoreactivity was detected in normal, hyperplastic and neoplastic breast epithelium. Expression of the bcl-2 protein was detected in 40% of carcinomas (> 10% positive neoplastic cells) and 85.2% of the benign hyperplastic lesions. Bax protein expression was detected in 8.1% of the carcinomas and 5.3% in the hyperplastic group. Rb and p53 proteins were detected in 75.5% and 45.5% of carcinomas. No relationship was observed between bcl-2 expression and patient's age, tumour size, tumour type and grade, lymph node status, Rb protein expression and proliferation indices. However, a strong positive relationship was detected between bcl-2 and Bax (p = 0.008), estrogen (ER) (p = 0.007) and progesterone receptors' (PgR) status (p = 0.0003). An inverse correlation with p53 protein (p = 0.004) was detected. Furthermore, a strong correlation was also observed between pRb and p53 (p = 0.001). The results indicate that in breast cancer bcl-2 protein expression may be under hormonal control. Since the expression is bcl-2 protein was inversely correlated with p53 protein expression, we suggest that bcl-2 may be related with favourable outcome in breast cancer.
- Published
- 2000
48. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
- Author
-
Ioachim E, Kamina S, Demou A, Kontostolis M, Lolis D, and Agnantis NJ
- Subjects
- Adult, Aged, Breast Neoplasms pathology, Breast Neoplasms ultrastructure, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast ultrastructure, Carcinoma, Intraductal, Noninfiltrating chemistry, Carcinoma, Intraductal, Noninfiltrating pathology, Carcinoma, Intraductal, Noninfiltrating ultrastructure, Carcinoma, Lobular pathology, Carcinoma, Lobular ultrastructure, Cathepsin D analysis, Cell Division, ErbB Receptors analysis, Extracellular Matrix Proteins analysis, Female, Frozen Sections, Humans, Immunoenzyme Techniques, Ki-67 Antigen analysis, Matrix Metalloproteinase 3 analysis, Middle Aged, Proliferating Cell Nuclear Antigen analysis, Receptor, ErbB-2 analysis, Receptors, Estrogen analysis, Receptors, Progesterone analysis, Retinoblastoma Protein analysis, Subcellular Fractions chemistry, Tumor Suppressor Protein p53 analysis, Breast Neoplasms chemistry, Carcinoma, Ductal, Breast chemistry, Carcinoma, Lobular chemistry, Metallothionein analysis, Neoplasm Proteins analysis
- Abstract
Metallothionein (MT) is a low molecular weight, cysteine-rich, zinc-binding protein that may have a function in cellular repair processes, growth and differentiation. Using a monoclonal antibody (E9) to metallothionein, we investigated the immunohistochemical expression of MT in routinely fixed and paraffin-embedded tissue from 98 cases of female breast carcinomas. The MT expression was studied in comparison with the expression of the basement membrane (BM) antigens (type IV collagen, laminin), fibronectin, cathepsin D, adhesion molecule CD44, p53 protein, the pRb, c-erbB-2 oncoprotein, EGFR, stromelysin-1, proliferation indices (Ki-67, PCNA), steroid receptor content as well as with other conventional clinicopathological parameters of breast cancer. Strong MT expression was observed in the majority of tumour cells in 18.4% of tumours, focal MT positivity in 13.3% and almost complete lack of MT expression in 68.4% of cases (mean value 33.36 +/- 26.36). The MT expression in carcinoma cells was strongly associated with the DCIS component of the tumour (p < 0.0001). High values of MT were correlated with low steroid receptor status (p = 0.08 for ER receptor and p = 0.019 for PgR receptor content). MT positive cases were correlated with stromelysin-1 expression (p = 0.059) and cathepsin D (p = 0.058). These findings suggest that MT expression is characteristic of the early phase of breast carcinogenesis, possibly regulated by hormones, and could be a new potential prognostic marker in breast cancer.
- Published
- 1999
49. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
- Author
-
Ioachim EE, Athanassiadou SE, Kamina S, Carassavoglou K, and Agnantis NJ
- Subjects
- Carcinoma, Ductal, Breast pathology, Cathepsin D analysis, Collagen analysis, ErbB Receptors analysis, Female, Fibronectins analysis, Humans, Ki-67 Antigen analysis, Laminin analysis, Lymphatic Metastasis, Lymphocytes, Tumor-Infiltrating pathology, Matrix Metalloproteinase 3 analysis, Mitotic Index, Prognosis, Proliferating Cell Nuclear Antigen analysis, Receptor, ErbB-2 analysis, Receptors, Estrogen analysis, Receptors, Progesterone analysis, Tumor Suppressor Protein p53 analysis, Breast Neoplasms enzymology, Breast Neoplasms pathology, Matrix Metalloproteinase 3 biosynthesis
- Abstract
Matrix metalloproteinases (MMPs) are a group of enzymes thought to be responsible for both normal connective tissue matrix remodelling and accelerated breakdown associated with tumour development. The current study aimed to investigate the immunohistochemical expression of matrix metalloproteinase 3 (MMP-3, stromelysin-1) in correlation with the expression of Basement Membrane (BM) antigen (type IV collagen, laminin), fibronectin, cathepsin D, p53, c-erbB-2, proliferative activity (Ki-67, PCNA), steroid receptor content as well as to the other conventional clinicopathological parameters in breast cancer. This study was performed on a series of frozen and paraffin sections from 84 breast cancer specimens by immunohistochemistry using the monoclonal antibody MMP-3 (Ab-1). Stromelysin-1 (ST1) was observed in about 10% of epithelial cells in the control groups (cases of fibrocystic and benign proliferative breast disease), while expression (> 10% of expression) was detected in 89.7% of tumours. The expression of ST1 in carcinoma cells was strongly associated with its presence in the stroma (p < 0.001). A significantly positive correlation was found between ST1 expression, and p53 tumour suppressor gene product (p = 0.004), and a relationship with c-erbB-2 protein and progesterone receptor status was also indicated. These findings suggest that ST1 expression in breast cancer tissue is irrespective of the expression of the extracellular matrix component, the proteolytic enzyme cathepsin D and the growth fraction of the tumour, and that it could be a potential new prognostic marker in breast cancer.
- Published
- 1998
50. Hemolytic uremic syndrome and thymic dysplasia in an infant.
- Author
-
Andronikou S, Kollios K, Dimou S, Kamina S, Bourantas K, and Papadopoulou ZL
- Subjects
- Humans, Infant, Male, Hemolytic-Uremic Syndrome pathology, Thymus Gland pathology
- Abstract
A 33-day-old male infant was admitted to the neonatal intensive care nursery because of respiratory distress, grunting, cyanosis, and radiological findings of bilateral bronchopneumonia. He responded well to intensive therapy, but 11 days later developed hemolytic uremic syndrome, which was treated conservatively with prednisone and plasma transfusions with good response. The hemolytic uremic syndrome resolved, but he subsequently developed severe recurrent infections of unknown etiology and died at the age of 78 days. Necropsy findings revealed necrotizing enterocolitis as well as dysplasia of the thymus and other lymphoid tissues, compatible with the diagnosis of immunodeficiency disorder.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.